NERV News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

NE

Mkt Cap

$112.5M

Volume

71.47K

Next Earnings

November 4th

Loading chart

NE

NERVMinerva Neurosciences, Inc

NERV

Pay with—

Available Balance0.00

NE

Mkt Cap

$112.2M

Volume

71.47K

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

Minerva Neurosciences to Participate in Two Upcoming Investor ConferencesMinerva Neurosciences announced participation in two upcoming investor conferences (Wells Fargo Healthcare Conference on September 8 and Cantor Global Healthcare Conference on September 9, 2026). The company is conducting a confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia, with topline efficacy data expected in the second half of 2027. The company has also established a Scientific Advisory Board of leading experts in psychiatry and neuroscience.GlobeNewswire Inc. · Aug 28, 2026

Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS ForumMinerva Neurosciences announced that CEO Remy Luthringer will present at The Stifel 2026 Virtual CNS Forum on March 18, 2026. The company is a clinical-stage biopharmaceutical firm focused on CNS disorder treatments, currently initiating a confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia.GlobeNewswire Inc. · Mar 12, 2026

Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business UpdatesMinerva Neurosciences reported FY2025 results with a net loss of $293.4 million (primarily due to $321.5 million in non-cash warrant and preferred stock issuance expenses). The company secured $80 million in gross proceeds from a private placement in October 2025 and plans to initiate a confirmatory Phase 3 trial for roluperidone for negative symptoms of schizophrenia in Q2 2026, with topline data expected in 2H 2027. Cash position improved to $82.4 million from $21.5 million year-over-year.GlobeNewswire Inc. · Mar 11, 2026

Minerva Stock Rises After Securing $200M for Schizophrenia Drug TrialMinerva Neurosciences secured a $200 million funding agreement to support its Phase 3 trial for roluperidone, a drug targeting negative symptoms of schizophrenia. The funding includes immediate $80 million and potential additional tranches, with investors like Vivo Capital and Janus Henderson participating.Benzinga · Oct 21, 2025

Schizophrenia Market to Witness Significant Growth by 2034 Across 7MM as New Therapies Enter Late-Stage Trials | DelveInsightThe schizophrenia market is expected to grow significantly by 2034, driven by rising disease prevalence, expanding approved therapies, and the anticipated launch of new treatments such as Olanzapine LAI, Iclepertin, Ulotaront, and Brilaroxazine.GlobeNewswire Inc. · May 1, 2025

Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates - Zacks Investment ResearchCartesian Therapeutics announced positive top-line results from its mid-stage study evaluating lead candidate Descartes-08 in patients with generalized myasthenia gravis. The study achieved its primary endpoint, with 71% of MG patients treated with Descartes-08 showing significant improvements in MG Composite score compared to 25% with placebo.Zacks Investment Research · Jul 3, 2024

Roche's (RHHBY) Ocrevus Subcutaneous Gets European Commission NodRoche (RHHBY) obtains approval for the subcutaneous formulation of relapsing multiple sclerosis drug Ocrevus in Europe. In addition, a review of the company's MAA for gene therapy, Elevidys, is also underway.Zacks Investment Research · Jun 25, 2024

Bristol Myers' (BMY) Krazati Gets FDA Nod for Colorectal CancerBristol Myers (BMY) wins FDA approval for Krazati, in combination with Erbitux, as a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer.Zacks Investment Research · Jun 24, 2024

Roche (RHHBY), Ascidian Team Up for RNA Exon Editing TherapeuticsRoche (RHHBY) gets exclusive, target-specific rights to Ascidian's RNA exon editing technology for undisclosed neurological targets for an initial payment of $42 million.Zacks Investment Research · Jun 19, 2024

Roche (RHHBY) Reports Upbeat Data on Columvi From STARGLO StudyRoche's (RHHBY) Columvi significantly extends survival in patients with relapsed or refractory diffuse large B-cell lymphoma in the phase III STARGLO study.Zacks Investment Research · Jun 17, 2024

to start trading

NE

NERVMinerva Neurosciences, Inc

NERV

Pay with—

Available Balance0.00

Your PositionYou don't own any NERV yet.

Related Tickers

Earnings